Author: Willem van Lawick

Leiden, The Netherlands – 13 December 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has appointed industry leader and former Genzyme CEO, Mr. Henri Termeer as Strategic Advisor. His role at Prosensa will be to provide input on the company’s corporate strategy and growth plans.

Amsterdam, The Netherlands, November 20, 2012 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has raised EUR 10 million in an equity financing round.

Cork, Ireland and Ghent, Belgium – 5 November 2012 – The European Union has awarded 6 million euro of research funding under the FP7-health framework to a consortium which is working to bring a predictive test for pre-eclampsia to market. The consortium is coordinated by Prof Louise Kenny at University College Cork, Ireland and driven… Continue reading International Consortium Awarded €6M to Validate Pre-Eclampsia

Amsterdam, The Netherlands, 31 October 2012 – MedSciences Capital is pleased to announce that its portfolio company, Net Medical B.V., has been acquired by Medizorg B.V. for an undisclosed cash amount. Net Medical develops and commercialises e-health solutions for out-patient clinics, clinical research organisations and hospitals. Their systems allow better monitoring of patient care, translating… Continue reading MSC portfolio company Net Medical is acquired by leading Dutch home care provider Medizorg

Leiden, The Netherlands, 23 October 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.